Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

[News]

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

More... (http://www.news-medical.net/news/20101204/Zometa-improves-OS-PFS-in-newly-diagnosed-multiple-myeloma-patients-Phase-III-study.aspx)